Department of Cardiology, Bern University Hospital, 3010, Bern, Switzerland.
Clinical Trials Unit, Bern University, Bern, Switzerland.
Eur Heart J. 2015 Feb 21;36(8):490-500. doi: 10.1093/eurheartj/ehu373. Epub 2014 Sep 2.
The effect of long-term high-intensity statin therapy on coronary atherosclerosis among patients with acute ST-segment elevation myocardial infarction (STEMI) is unknown. The aim of this study was to quantify the impact of high-intensity statin therapy on plaque burden, composition, and phenotype in non-infarct-related arteries of STEMI patients undergoing primary percutaneous coronary intervention (PCI).
Between September 2009 and January 2011, 103 STEMI patients underwent intravascular ultrasonography (IVUS) and radiofrequency ultrasonography (RF-IVUS) of the two non-infarct-related epicardial coronary arteries (non-IRA) after successful primary PCI. Patients were treated with high-intensity rosuvastatin (40 mg/day) throughout 13 months and serial intracoronary imaging with the analysis of matched segments was available for 82 patients with 146 non-IRA. The primary IVUS end-point was the change in per cent atheroma volume (PAV). After 13 months, low-density lipoprotein cholesterol (LDL-C) had decreased from a median of 3.29 to 1.89 mmol/L (P < 0.001), and high-density lipoprotein cholesterol (HDL-C) levels had increased from 1.10 to 1.20 mmol/L (P < 0.001). PAV of the non-IRA decreased by -0.9% (95% CI: -1.56 to -0.25, P = 0.007). Patients with regression in at least one non-IRA were more common (74%) than those without (26%). Per cent necrotic core remained unchanged (-0.05%, 95% CI: -1.05 to 0.96%, P = 0.93) as did the number of RF-IVUS defined thin cap fibroatheromas (124 vs. 116, P = 0.15).
High-intensity rosuvastatin therapy over 13 months is associated with regression of coronary atherosclerosis in non-infarct-related arteries without changes in RF-IVUS defined necrotic core or plaque phenotype among STEMI patients.
长期高强度他汀类药物治疗对急性 ST 段抬高型心肌梗死(STEMI)患者的冠状动脉粥样硬化的影响尚不清楚。本研究旨在定量评估高强度他汀类药物治疗对行直接经皮冠状动脉介入治疗(PCI)的 STEMI 患者非梗死相关动脉斑块负荷、组成和表型的影响。
2009 年 9 月至 2011 年 1 月,103 例 STEMI 患者成功行直接 PCI 后,对 2 条非梗死相关的心外膜冠状动脉(非 IRA)进行血管内超声(IVUS)和射频超声(RF-IVUS)检查。所有患者均接受高强度瑞舒伐他汀(40mg/天)治疗 13 个月,82 例患者(146 个非 IRA)有连续的冠状动脉内成像和匹配节段的分析。主要 IVUS 终点为斑块体积百分比(PAV)的变化。13 个月后,低密度脂蛋白胆固醇(LDL-C)中位数从 3.29mmol/L 降至 1.89mmol/L(P<0.001),高密度脂蛋白胆固醇(HDL-C)水平从 1.10mmol/L 升至 1.20mmol/L(P<0.001)。非 IRA 的 PAV 降低了 0.9%(95%CI:-1.56 至 -0.25,P=0.007)。至少有 1 条非 IRA 出现消退的患者(74%)多于未出现消退的患者(26%)。坏死核心百分比无变化(-0.05%,95%CI:-1.05 至 0.96%,P=0.93),RF-IVUS 定义的薄帽纤维粥样斑块数量也无变化(124 个 vs. 116 个,P=0.15)。
高强度瑞舒伐他汀治疗 13 个月与 STEMI 患者非梗死相关动脉的冠状动脉粥样硬化消退有关,而在 STEMI 患者中,RF-IVUS 定义的坏死核心或斑块表型无变化。